Decision/Conclude agreement
Proposed

方達控股目標業務出售予Charles River Laboratories

Tigermed's privatization of Frontage Holdings splits its business, with the bioanalytical and DMPK target business to be sold to Charles River Laboratories at a preliminary valuation of about US$470 million.

Trajectories

Sign-in readers can mine up to three arcs for this record.

Sign in to get trajectories

Actors and targets

Targets Charles River Laboratoriesactor生物分析及藥物代謝動力學(DMPK)等目標業務item

Source

生物分析及藥物代謝動力學(DMPK)等目標業務將出售予Charles River Laboratories,初步估值約4.7億美元
stockintelligencenews · Telegram Open post

Extracted detail

Bank
瑞銀
Currency
USD

Related decisions

Same kind only, ranked by embedding similarity to this record.